<DOC>
	<DOCNO>NCT00407524</DOCNO>
	<brief_summary>This study aim provide scientific evidence efficacy safety agent 'add-on ' therapy adult patient whose asthma remain uncontrolled standard medication . The aims ass efficacy , safety tolerability AKL 1 companred placebo treatment asthma .</brief_summary>
	<brief_title>AKL 1 Asthma Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . The patient either sex age 18 70 year , inclusive . 2 . The patient receive verbal write study information , question answer satisfactorily consent form personally sign dated patient investigator . 3 . The patient diagnosis persistent chronic bronchial asthma ( reference Global Initiative Asthma ( GINA ) guideline , NIH , NHLBI . Global Initiative asthma . NIH Publication no.963659B . Bethesda , MD : NID 1998 ) ) . 4 . The patient FEV1 ( % predict ) &gt; 60 % Visit 1 . 5 . The patient positive reversibility test ( history ) &gt; equal 15 % improvement FEV1 15 30 minute inhalation least 200 ug salbutamol ( beta2adrenergic agonist administration ) PEF variability 20 % described current BTS/SIGN guideline ( British Thoracic Society , Scottish Intercollegiate Guideline Network . British Guidelines Management Asthma . Thorax 2003 ; 58:194 . 6 . Females must postmenopausal ( &gt; 1 year ) , surgically sterile use adequate contraception ( hormonal contraception , intrauterine device ) , breastfeed negative serum pregnancy test . 7 . The patient satisfactory health exception asthma determine investigator basis medical history physical examination . 8 . In investigator ’ judgment , patient able willing comply Study Visits procedure ( include laboratory test , lung function test ) , accurate timely completion electronic asthma diary 1 . The patient poorly control asthma define require course oral parenteral corticosteroid , admission hospital asthma ( include treatment emergency room ) , exacerbation asthma three month prior Visit 1 ( investigator ’ judgment ) . 2 . Maintenance oral corticosteroid treatment . 3 . The patient seasonal asthma alone . 4 . Use unlicensed dos inhale corticosteroid medication ( &gt; 2000mcg beclomethasone diproprionate/ day equivalent ) . 5 . The patient know laboratory abnormality , opinion investigator , would contraindicate study participation , include , blood urea nitrogen ( BUN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; equal 1.5 x upper limit normal ( ULN ) creatinine &gt; 1.5 mg/dL . 6 . The patient unable discontinue shortacting beta2adrenergic agonist least 4 hour prior Screening Visit . 7 . The patient chronic heart failure class III IV ( New York Heart Association ) . 8 . The patient recent ( less six month ) history stroke , transient ischemic attack myocardial infarction . 9 . The patient history know alcohol substance abuse within oneyear prior Visit 1 . 10 . The patient able follow study procedure ( e.g. , language problem , psychological disorder ) consider noncompliant accord investigator . 11 . The patient active malignancy type history malignancy ( exception patient malignancy surgically remove evidence recurrence within five year enrolment , patient history treat basal cell carcinoma ) . 12 . The patient severe acute chronic medical psychiatric condition may increase risk associate study participation study drug administration may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study 13 . The patient significant uncontrolled chronic disease , hepatic renal insufficiency , opinion investigator , would contraindicate study participation confound interpretation result . 14 . The patient difficulty swallow capsule tablet , dysphagia unable tolerate oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>